IsoPlexis Full Year 2022 Earnings: Misses Expectations

IsoPlexis (NASDAQ:ISO) Full Year 2022 Results

Key Financial Results

• Revenue: US$16.8m (down 2.9% from FY 2021).
• Net loss: US$106.0m (loss widened by 15% from FY 2021).
• US$2.70 loss per share.

All figures shown in the chart above are for the trailing 12 month (TTM) period

IsoPlexis Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 21%.

Looking ahead, revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 5.8% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for IsoPlexis (2 are concerning!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.